Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News United Therapeutics Corp UTHR

Healthcare Biotechnology
United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended... see more

Recent & Breaking News (NDAQ:UTHR)

Barclays Downgrades 5 Biopharma Stocks, Upgrades Pfizer And Alexion

Benzinga.com  November 29, 2016

Research Reports Initiation on Drug Makers Stocks -- Amphastar Pharma, United Therapeutics, MEI Pharma, and SciClone Pharma

PR Newswire November 15, 2016

SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating United Therapeutics Corporation for Potential Breaches Of Fiduciary Duty By Its Board of Directors

PR Newswire October 31, 2016

United Therapeutics Corporation Reports Third Quarter 2016 Financial Results

PR Newswire October 27, 2016

United Therapeutics Corporation To Report Third Quarter 2016 Financial Results Before The Market Opens On Thursday, October 27, 2016

PR Newswire October 20, 2016

United Therapeutics Corporation Announces Executive Leadership Changes

PR Newswire April 28, 2016

United Therapeutics Corporation Reports First Quarter 2016 Financial Results

PR Newswire April 28, 2016

United Therapeutics Corporation To Present At Deutsche Bank 41st Annual Health Care Conference

PR Newswire April 27, 2016

SteadyMed Announces Public Availability of PTAB Decision to Institute Inter Partes Review Proceedings

GlobeNewswire April 25, 2016

United Therapeutics Corporation To Announce First Quarter 2016 Financial Results Before Market Open On Thursday, April 28, 2016

PR Newswire April 20, 2016

SteadyMed to Host an Analyst and Investor Reception

GlobeNewswire April 14, 2016

SteadyMed Announces Initiation of Inter Partes Review Proceedings by U.S. Patent and Trademark Office Against a United Therapeutics Patent

GlobeNewswire April 11, 2016

United Therapeutics Corporation To Present At Barclays Global Healthcare Conference

PR Newswire March 8, 2016

United Therapeutics Corporation Reports 2015 Fourth Quarter And Annual Financial Results

PR Newswire February 25, 2016

United Therapeutics Corporation To Announce Fourth Quarter And Annual 2015 Financial Results Before Market Open On Thursday, February 25, 2016

PR Newswire February 18, 2016

United Therapeutics Receives Paragraph IV Notice Letter For Orenitram

PR Newswire February 18, 2016

United Therapeutics Corporation To Present At 34th Annual J.P. Morgan Healthcare Conference

PR Newswire January 6, 2016

SteadyMed Demonstrates Potential for Reduced Infusion Site Sensitivity Associated With Trevyent Compared to Remodulin

GlobeNewswire December 7, 2015

United Therapeutics Corporation Reports Third Quarter 2015 Financial Results

PR Newswire October 27, 2015

SteadyMed Files Inter Partes Review to Invalidate United Therapeutics Patent

GlobeNewswire October 21, 2015